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Background: Female sterilization is the second most commonly used method of contraception in the United
States. Female sterilization can now be performed through laparoscopic, abdominal, or hysteroscopic approaches.
The hysteroscopic sterilization may be a safer option than sterilization through laparoscopy or laparotomy because
it avoids invading the abdominal cavity and undergoing general anaesthesia. Hysteroscopic sterilization mainly
includes chemical agents and mechanical devices. Common issues related to the toxicity of the chemical agents
used have raised concerns regarding this kind of contraception. The difficulty of the transcervical insertion of such
mechanical devices into the fallopian tubes has increased the high incidence of device displacement or
dislodgment. At present, Essure® is the only commercially available hysteroscopic sterilization device being used
clinically. The system is irreversible and is not effective immediately.
Presentation of the hypothesis: Our new hysteroscopic sterility system consists of nickel-titanium (NiTi) shape
memory alloy and a waterproof membrane. The NiTi alloy is covered with two coatings to avoid toxic Ni release
and to prevent stimulation of epithelial tissue growth around the oviducts. Because of the shape memory effect of
the NiTi alloy, the device works like an umbrella: it stays collapsed at low temperature before placement and opens
by the force of shape memory activated by the body temperature after it is inserted hysteroscopically into
the interstitial tubal lumen. The rim of the open device will incise into interstitial myometrium during the
process of unfolding. Once the device is fixed, it blocks the tube completely. When the patient no longer
wishes for sterilization, the device can be closed by perfusing liquid with low temperature into the uterine
cavity, followed by prospective hysteroscopic removal. After the device removal, the fallopian tube will revert
to its physiological functions.
Testing the hypothesis: Currently, experimental and clinical studies are needed to attest the safety, efficiency
and reversibility of the novel sterilization device.
Implications of the hypothesis: If our hypothesis is confirmed, appropriate and reversible contraceptive can
be achieved with the device we have designed, which may have significant repercussions for numerous
women worldwide.
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Hysteroscopic sterilization is a safer option than sterilization
through laparoscopy or laparotomy because it avoids ab-
dominal cavity invasion and the use of general anaesthesia.
Moreover, this procedure can be performed in an out-
patient setting by an incision-free route, with a shorter re-
covery period, and at a lower cost [1-4]. Scholars around
the world devote themselves to the research of new tech-
nologies for female sterilization, including methods that
involve tubal occlusion, mainly by using chemical agents
combined with a sclerosing agent [5], cyanoacrylate [6],
n-butyl-2-cyanoacrylate adhesive [7], and polidocanol [8].
Other mechanical devices such as in situ-gelling polymeric
device [9], implant with two sets of six slots [10], or intes-
tine submucosal device [11] are also under investigation.
The main concerns are related to the toxicity of the chem-
ical agents on the tubal epithelium, peritoneum, and pelvic
organs. Additionally, the transcervical insertion of the
mechanical device into fallopian tube may be technically
challenging, resulting in a high incidence of device dis-
placement or dislodgment [12]. The methods mentioned
above are not currently in use in a clinical setting.
Gradually, with the development of material science,
shape memory materials (SMMs), including shape mem-
ory alloys (SMAs) and shape memory polymers (SMPs),
have attracted a lot of attention because of their unique
characteristics and super elasticity. SMMs have the cap-
ability of “memorizing” and recovering their permanent
shape (SP) from an original temporary shape when sub-
jected to an appropriate temperature or other particular
stimuli. Therefore, a bulky device could potentially be
implanted in a relatively small space in a compressed
temporary shape through less invasive surgery. Once
in place, it can be expanded to its previously defined
size or shape to fit the space as required [13-16]. The
application of SMMs for the sterilization purposes,
two studies including a SMP device [12] and an oviduct
plugs with nickel-titanium (NiTi) shape memory alloy
and silicone rubber [17] are under study in animal ex-
periments in China. Additionally, Essure® (Conceptus
Incorporated, Mountain View, CA, USA) is a most prom-
ising transcervical sterilization device, and its body is
made of NiTi shape memory alloy [18]. This system was
approved by the US Food and Drug Administration
(FDA) in 2002. Currently, it is the only commercially
available hysteroscopic sterilization device used in clinical
practice, since the Adiana® Permanent Contraception
System (Hologic, Inc., Bedford, MA, USA), approved
by the FDA in 2009, was removed from the US mar-
ket by the manufacturer in 2012 [19,20]. Both Essure®
and Adiana® contraception systems were proven effi-
cacious and safe by relatively short-term clinical trial data.
Very few pregnancies occurred among women with
confirmed bilateral tubal occlusion achieved with bothhysteroscopic methods. However, long-term data beyond
7 years is unavailable. According to the FDA directions
and product labelling, bilateral tubal occlusion must be
confirmed 3 months after device implantation mainly by
performing hysterosalpingogram (HSG). At this time, the
fallopian tubes undergo fibrosis, which leads to tubal oc-
clusion and causes the contraceptive effect. Thus, patients
must use alternative contraception for at least 3 months
post procedure. Even at that time, if bilateral tubal occlu-
sion is not confirmed, the patient should continue alterna-
tive contraception for 3 additional months. Pregnancies
that occurred while either one of these devices was in
place were attributed to lack of follow-up, improper use of
alternative contraception, failure of alternative contracep-
tion, or misinterpretation of HSG results [19-21].
Aside from the lack of immediate effect, another limita-
tion is that both systems approved by FDA are irreversible.
In fact, in the United States, the overall cumulative prob-
ability of expressing regret within 14 years after tubal
sterilization was 20.3% for women aged 30 years or younger
and 5.9% for women over the age of 30 years at the
time of sterilization. However, after permanent hystero-
scopic sterilization, the opportunity to undergo sterilization
reversal seems unlikely. Some requests for sterilization re-
versal were followed by in vitro fertilization (IVF) proce-
dures. However, the impact of the Essure® coil on IVF
outcomes and pregnancy course is uncertain [22,23].
Therefore, we thought of developing a reversible and im-
mediately effective hysteroscopic sterilization method that
is safe and effective. In the present article, we describe a
micro-barrier contraception method by using shape mem-
ory alloy that can be easily inserted in the interstitial fallo-
pian tube in an outpatient setting. Our proposed method
may result in a low-cost, non-hormonal, long-term, re-
versible, and discreet method of contraception for women.
The presentation of hypothesis
The manufacture of the hysteroscopic sterilization device.
The device consists of an umbrella supporter made of
NiTi alloy and an umbrella fabric made of a waterproof
polyurethane-like membrane. Our device is 8 mm in
length and 1.5 mm in diameter when closed. Once
opened, the diameter of the umbrella fabric expands to
6.5 mm. One end (head) of the device is covered with a
semi-soft cap made of a biodegradable material. At the
other end (tail), there is a small fibre intended to facili-
tate removal. The NiTi alloy is covered with two coat-
ings. The first coating is silicon dioxide (SiO2) applied
using the sol–gel method to avoid toxic Ni release. The
second coating is a macromolecular substance with high
biological stability to prevent stimulation of epithelial tis-
sue of the oviduct growth. The candidates for the second
coating include poly (dimethylacrylamide) (PDMAA) and
poly (2-ethyloxazoline) (PEtOx), which represent anti-
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photochemical grafting method to reduce the unspecific
extracellular matrix-mediated adhesion of fibroblasts to
implant surfaces [24].
The device can change its size according to the
temperature.
NiTi alloy is a SMA, which “remembers” its original
and forged shape at a specified temperature. Basically,
SMA presents two well-defined phases: austenite and
martensite. The martensite phase consists of a SMA only at
low temperature range. Martensite is soft and can be easily
deformed by stress. When the temperature rises to austen-
ite activation temperature (As, the lowest temperature at
which the SMA starts to change its shape), the SMA re-
covers its shape toward the original and forged shape
gradually and completely when the temperature reaches
austenite final temperature (Af ). Then, when temperature
decreases, austenite starts to change its shape to martens-
ite at martensite start temperature (Ms) and completes
the transformation at martensite final temperature (Mf)
[14,25]. The device is like an umbrella that stays collapsed
before insertion; it is activated by body temperature
and subsequently opened by the force of shape memory
(see Figure 1). The umbrella fabric is supported by several
axes joined with a thin circular ring and covered with the
waterproof polyurethane-like membrane. The opened de-
vice anchors in the interstitial fallopian tube as a barrier
and prevents the sperm cells from coming in contact with
the ova.Figure 1 Illustration of the structure and working principle of the dev
like a folded umbrella which minimizes its size in diameter and subsequen
insertion into the interstitial portion, like an unfolded umbrella; (C) Coronal
tube, The device is anchored in the right place and the passage through th
membrane; 3. Guild rod; 4. A small hole; 5. The supporter of the shape
myometrium for fixation.The device can be placed hysteroscopically.
According to our hypothesis, when the device is inserted
via hysteroscopy, the temperature of the running disten-
sion fluid into the uterine cavity is low; thus, the device
maintains its collapsed shape. After it is inserted into the
interstitial tubal lumen, the device temperature rises to
body temperature; consequently, the device “remembers”
and returns to its originally forged shape. The rim of the
open device will incise into the interstitial myometrium
during the process of unfolding. The rim is very thin,
which facilitates the cut. Once the incision process is fin-
ished, the device is fixed to the interstitial myometrium.
The open device will obstruct the tube completely.
The device is a reversible sterilization method.
The device anchors in a very narrow part of the tube
and little tissue is damaged by the thin rim. Because the
device is coated with a highly stable macromolecular
substance, it is biologically inactive and cannot induce
tissue growth or encapsulation. When the patient wishes
to reverse sterilization, a liquid at low temperature is
perfused into the uterine cavity. Then device tail can be
used for its removal under hysteroscopy. Owing to litter
damage caused by the thin rim (diameter: 0.05-0.1 mm),
the scars in the fallopian tube will be very small. The fal-
lopian tube will revert to its function after the device is
removed.
Therefore, the design of the safe, reversible, and imme-
diately effective sterilization device was achieved. We
obtained a national patent in China for the inventionice. (A) The device before insertion into the tubal interstitial portion,
tly facilitates the insertion of the device; (B) The device after the
section view, the device is placed at the interstitial portion of the
e tube is completely blocked. 1. A semi-soft hat; 2. A waterproof
memory umbrella; 6. A thin circular rim to cut into the interstitial
Xu et al. Reproductive Biology and Endocrinology 2014, 12:61 Page 4 of 6
http://www.rbej.com/content/12/1/61of the sterilization device described herein. The appli-
cation number of the patent is ZL200810030905 [26]
(see Additional file 1: supplemental document S1 and
Additional file 2: supplemental document S2).
Testing the hypothesis
The core for testing our hypothesis is to successfully
manufacture the barrier contraceptive device by using
shape memory material and to test the device activation
and modification under different temperatures simulating
a normal range of body temperatures at our material la-
boratory. The testing process involved the following steps.
Step 1, to manufacture the device parts, including the
following:
(1) Manufacture the NiTi alloy adjust the NiTi alloy As
to 10 degrees centigrade and Af to 35 degrees
centigrade by changing the mixture proportions of
Ni and Ti and by applying a thermal treatment
technique in the laboratory;
(2) Manufacture the NiTi alloy supporter;
(3) Cover with both coatings and test the efficiency and
biocompatibility of the coatings;
(4) Manufacture the waterproof membrane made
of poly(dimethylacrylamide) (PDMAA) or
poly(2-ethyloxazoline) (PEtOx);
(5) Assemble the device supporter made of NiTi alloy
and the waterproof membrane.
Step 2, to manufacture 6 devices and test the effect of
the transformation from the closed shape to the opened
shape under simulated temperatures (under water) in
the material laboratory.
Step 3, to test the placement of the device and the ef-
fect of the transformation hysteroscopically under simu-
lated temperatures in a surgically excised uterus: placing
the device into the interstitial portion in a surgically ex-
cised uterus (with interstitial portions) by using the hys-
teroscopic catheterization technique.
Step 4, to conduct prospective, observational animal ex-
periments and then clinical studies to assess device safety,
efficacy and reversibility, that is, we will continue to test
the device and collect data on biocompatibility, successful
placement rate, obstruction rate, the contraceptive effect
and reversal of contraceptive effect, and any complications
(such as nickel allergies, infection, pain, and device dis-
placement) in animal experiments using goats and then a
preliminary clinical trial with a small sample size (about
10 to 15 patients: age ≥ 20 years, gravity ≥ 1, without infer-
tility). Necessarily, we will adjust and improve the design
of the device. If the preliminary clinical trial presents the
device is safe and effective, a large scale clinical trial (at
least 50 to 100 patients) will be conducted to evaluate the
device comprehensively.Implications of the hypothesis
It is predicted that the total world population will reach
8.9 billion in 2050 and more than 26 billion couples will
need contraceptives in the next half century. Although
steady progress in hormonal and non-hormonal modern
contraceptive research has been achieved over the past
50 years, the contraceptives available today have all kinds
of adverse effects and are not suitable for all users. A need
to expand contraceptive methods still exists [27,28].
Our efforts to develop a novel contraceptive device with
special characteristics make great sense. Two of the largest
advantages of this contraception method are reversibility
and immediate effectiveness. Essure®, the most promising
intratubal device available, consists of a stainless steel
inner coil, an outer coil of nitinol, and polyethylene ter-
ephthalate (PET) fibres. After insertion into the interstitial
portion of each fallopian tube by hysteroscopic guidance,
the outer coil expanded and anchored the device to the
fallopian tube. Over the next few weeks, fibrotic tissue
growth around the device by PET stimulating results in
complete tubal occlusion [29,30]. At last, tubal occlusion
and proper positioning must be confirmed at 3 months
postprocedure by performing a HSG, or a pelvic radio-
graph for both sterilization systems [30]. Owing to the ir-
reversible damage of the tube, the sterilization methods
are permanent. If patients wish to conceive again, they
must turn to IVF. Obviously, our reversible device is more
practical and allows patients to change their minds con-
cerning sterilization. Our device is the less invasive modal-
ity. Our device, with a uniquely designed shape, is 8 mm
in length, equivalent to the interstitial portion of fallopian
tube. There is no pressure from the oviduct peristalsis and
the device is relatively unlikely to be excluded by this
force. The difficulty of placement and possibility of perfor-
ation are lower. However, Essure®, for example, is 4 cm
long and anchors to a 3-cm segment of the tube. Bilateral
tube placement would fail if there is adhesion in the isth-
mus or ampulla portions of the fallopian tube. In addition,
several studies reported the use of Essure® devices in prox-
imal tubal occlusion in subfertile women with hydrosal-
pinges before IVF [31] and receiving IVF procedures with
the presence of the Essure® [32]. Although, researchers
favoured the outcome, the sample size was still very small.
Further, there is concern that intrauterine coils of Essure®
could interfere with subsequent IVF procedures [29].
Therefore, a safe and effective hysteroscopic sterilization
method is needed urgently.
In theory, the development consists of attractive ad-
vantages such as the long-term, easy-placement, revers-
ible and immediately effective. If it is really effective, it
may have significant repercussions for numerous women
worldwide. However, the device obstructs the fallopian
tube mechanically by a waterproof polyurethane-like
membrane rather than destroys the cavity of tube and
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brotic tissue as Essure®. Theoretically, our device would
have a lower contraceptive success rate. Therefore, the
corrosion resistance, stability and tenacity of the water-
proof membrane need further research. In addition,
whether the scars in the fallopian tube caused by the de-
vice placement could lead to impaired tubal motility
and, thereby, impact on fertility negatively after removal
of the devices also is an important part of our study in
the future. For these reasons, repeated animal experi-
ments and subsequent clinical studies are now needed to
attest the safety and efficiency of the novel contraceptive
device and improve it continuously.Additional files
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